Start Date
August 12, 2020
Primary Completion Date
September 10, 2024
Study Completion Date
December 15, 2024
IMC-I109V Single Ascending Dose
Single dose administration of IMC-I109V
IMC-I109V Multiple Ascending Doses
Multidose administration of IMC-I109V
HBV HCC Module MAD
Multidose administration of IMC-I109V
Taipei Veterans General Hospital, Taipei
St. Vincent's Hospital, Fitzroy
Aarhus University, Aarhus
Hospital Ramón and Cajal, Madrid
University Hospitals Cleveland Medical Center Case Western Reserve, Cleveland
Pusan National University Hospital, Busan
Kaohsiung Medical University Chung-Ho, Kaohsiung City
University of Southern California Keck School of Medicine, Los Angeles
The Alfred Centre, Melbourne
Queen Mary Hospital, Hong Kong
ARENSIA Exploratory Medicine Research Clinic, Bucharest
Hospital Universitari Vall d'Hebron de Barcelona, Barcelona
Guy's Hospital, Dept. of Infectious Disease, London
Chelsea and Westminster Hospital, Research and Development, Clinical Trials Facility, London
Nottingham University Hospitals NHS Trust Biomedical Research Centre, Nottingham
Lead Sponsor
Immunocore Ltd
INDUSTRY